Special issue on development and advancement of biomarker technologies

Published 12 July, 2021

Biomarker technologies have numerous applications, including disease diagnosis, treatment prognosis and drug development in medical settings. They are also used in molecular epidemiological studies to indicate exposures, to measure early effects and to assess human susceptibility. Most recently, the CRISPR, known for its role in gene editing, has become a cutting-edge biological sensor tool to detect viral agents, gene expression changes and environmental contaminants. The application of artificial intelligence and machine learning (AI/ML) technology in healthcare and cancer diagnosis is still nascent. Like any other type of novel technology, CRISPR or AI/ML needs to be adequately vetted prior to being widely adopted. Developing highly-sensitive, specific and cost-effective biomarker technologies presents a large challenge. In this special issue, we are seeking papers that consider all types of biomarker method development, advancement and application, not only in research fields, but also in clinical settings. High-quality narrative, commentary and systematic reviews will also be considered.

Topics Covered:

These will include, but not be limited to:

  • Development of new biomarker technologies
  • Improvement of current biomarker methods
  • Application of CRISPR screening and/or other cutting-edge techniques for biomarker discovery
  • Advancement of multi-omics for biomarker discovery
  • Dynamic biomarker discovery for any areas of studies

Important Dates and Deadlines:

  • Submission deadline: rolling submission

Submission Instructions:

Please read the Guide for Authors before submitting. All articles should be submitted online

Guest Editors:

  • Dr. Christa Noehammer, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Austria. Email: christa.noehammer@ait.ac.at
  • TBN

Back to Call for Papers

Stay Informed

Register your interest and receive email alerts tailored to your needs. Sign up below.